There will be many combination trials as more drugs with efficacy potential, like ours, get to late stage testing. AD is complex and very likely to require combination therapies to treat it.
There's a lot of nonsense here about Anavex "competitors" and "junk". Anti-plaque/tangle drugs are not competitors to an S1 agonist. Nor any other drug with a different MOA. BP is not conspiring against us, nor the AD research community. Folks should ignore that.
Market Data 
Markets 
AI
